Company news

Regeneron Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Regeneron Announces Start of REGN-COV2 Phase 3 COVID-19 Prevention Trial in Collaboration with National Institute of Allergy and Infectious Diseases (NIAID)

July 5, 2020

Regeneron and Sanofi Provide Update on Kevzara® (sarilumab) Phase 3 U.S. Trial in COVID-19 Patients

July 1, 2020

Regeneron Announces the 2020 Winners of the Regeneron Prize for Creative Innovation

June 21, 2020

FDA Approves New Dupixent® (dupilumab) Pre-filled Pen Designed to Support More Convenient Self-Administration

June 18, 2020

Regeneron Begins First Clinical Trials of Anti-Viral Antibody Cocktail REGN-COV2 for the Treatment and Prevention of COVID-19

June 10, 2020

Regeneron Announces Virtual-Only Format for 2020 Annual Meeting of Shareholders

June 7, 2020

Regeneron Announces Upcoming Investor Conference Presentations

June 4, 2020

Regeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based Treatments

May 31, 2020

Regeneron Completes Secondary Offering of Common Stock Held by Sanofi

May 28, 2020

Regeneron Announces Pricing of Secondary Offering of its Common Stock Held by Sanofi

May 25, 2020

Regeneron Announces Secondary Offering of its Common Stock Held by Sanofi and $5 Billion Stock Repurchase

May 24, 2020

Regeneron and Colorado Center for Personalized Medicine Announce Major New Human Genetics Research Collaboration

May 10, 2020

Regeneron Reports First Quarter 2020 Financial and Operating Results

May 4, 2020

Regeneron and Sanofi Provide Update on U.S. Phase 2/3 Adaptive-Designed Trial of Kevzara® (sarilumab) in Hospitalized COVID-19 Patients

April 26, 2020

FDA Accepts for Priority Review Biologics License Application for REGN-EB3 to Treat Ebola

April 15, 2020

Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody)

April 7, 2020

Regeneron Finalizes Praluent® (alirocumab) Restructuring and Updates Accounting Presentation

April 5, 2020

Dupixent® (dupilumab) Phase 3 Data at Revolutionizing Atopic Dermatitis Conference Show Significant Improvement in Severe Atopic Dermatitis for Children Aged 6 to 11 Years

April 2, 2020

Regeneron Announces American College of Cardiology Presentation of Positive Phase 3 Evinacumab Results in Patients with Severe Inherited Form of High Cholesterol

March 29, 2020

← Newer news releases

Calls

The 5 newest of 32 calls. Every call is listed under its year.

Decks

The 5 newest of 64 decks. Every deck is listed under its year.